secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akero Therapeutics, Inc. (—)
CIK:        0001744659
Form:       8-K
Filed at:   2024-05-10T23:59:59+00:00
Accession:  0001193125-24-135733
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akero Q1 2024 cash $903.7M; Phase 2b HARMONY week 96 fibrosis improvement 75% for 50mg EFX
--------------------------------------------------------------------------------

- Cash, equivalents and short-term marketable securities $903.7M as of March 31, 2024; March equity offering raised ~$366.9M gross.
- Phase 2b HARMONY Week 96: 75% (50mg) and 46% (28mg) achieved ≥1-stage fibrosis improvement without MASH worsening vs 24% placebo (p<0.001 and p=0.07).
- 36% (50mg) and 31% (28mg) showed 2-stage fibrosis improvement vs 3% placebo (p<0.01).
- Total operating expenses $60.0M vs $28.8M YoY on increased R&D for Phase 3 studies.
- Phase 3 SYNCHRONY Histology and Real-World enrolling; Outcomes trial on track to start Q2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1744659/000119312524135733/0001193125-24-135733-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1744659/000119312524135733/d836734d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-135733

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer